Sponsor or institution
Clinical trials and research at Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
As of November 12, 2026, Find a Trial lists 6 clinical trials run by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. that are recruiting, in China. By phase: Phase 2/3 (3), Phase 3 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Sintilimab with chemotherapy, with or without ipilimumab, for resectable stomach/GEJ cancer | Phase 2/3 | Guangzhou, Guangdong | Recruiting | Jun 11, 2026 |
| IBI3028 in advanced solid tumors | Phase 1 | Tianjin, Tianjin Municipality | Recruiting | May 15, 2026 |
| IBI310 with sintilimab as first-line treatment for hepatocellular carcinoma | Phase 2/3 | Hefei, Anhui and 1 other locations | Recruiting | Mar 24, 2026 |
| IBI354 with or without pertuzumab versus taxane plus trastuzumab and pertuzumab for HER2-positive metastatic breast cancer | Phase 3 | Beijing, Beijing Municipality | Recruiting | Jan 30, 2026 |
| Picankibart for people with active psoriatic arthritis | Phase 2/3 | Hangzhou, Zhejiang | Recruiting | Dec 19, 2025 |
| IBI112 for adolescents with moderate to severe plaque psoriasis | Phase 3 | Beijing, Beijing Municipality | Recruiting | Dec 4, 2025 |
All recruiting trials (6)
-
Sintilimab with chemotherapy, with or without ipilimumab, for resectable stomach/GEJ cancer
A randomized trial tests whether adding sintilimab (and possibly ipilimumab) to standard chemotherapy around surgery helps people with resectable stomach or gastroesophageal junction cancer.
-
IBI3028 in advanced solid tumors
This phase 1 study tests IBI3028 in adults with unresectable or metastatic solid tumors to see if it is safe and how patients tolerate it.
-
IBI310 with sintilimab as first-line treatment for hepatocellular carcinoma
This trial will test whether combining IBI310 with sintilimab works and is safe as a first-line option for people with advanced or metastatic hepatocellular carcinoma who have not received systemic therapy and are not candidates for curative local treatments.
-
IBI354 with or without pertuzumab versus taxane plus trastuzumab and pertuzumab for HER2-positive metastatic breast cancer
This trial tests whether IBI354, with or without pertuzumab, works better than standard taxane plus trastuzumab and pertuzumab as first-line treatment for adults with HER2-positive unresectable locally advanced or metastatic breast cancer.
-
Picankibart for people with active psoriatic arthritis
This trial tests whether subcutaneous picankibart can improve joint and skin symptoms in adults with active psoriatic arthritis who have not had enough benefit from NSAIDs or non-biologic DMARDs.
-
IBI112 for adolescents with moderate to severe plaque psoriasis
This trial will test whether the drug IBI112 can improve skin symptoms and is safe for adolescents aged 12–18 who have moderate to severe plaque psoriasis compared with a placebo.
Quick answers
How many clinical trials run by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2/3: 3, Phase 3: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.